Standard BioTools (NASDAQ:LAB - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Standard BioTools has set its FY 2024 guidance at EPS.Investors interested in participating in the company's conference call can do so using this link.
Standard BioTools (NASDAQ:LAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.05. The firm had revenue of $28.19 million for the quarter, compared to analysts' expectations of $28.00 million. On average, analysts expect Standard BioTools to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Standard BioTools Price Performance
Shares of LAB stock traded up $0.06 during trading on Wednesday, hitting $2.54. 2,528,580 shares of the stock traded hands, compared to its average volume of 2,252,896. The firm has a market capitalization of $736.90 million, a P/E ratio of -2.67 and a beta of 1.64. Standard BioTools has a 52-week low of $1.46 and a 52-week high of $3.16. The firm's fifty day moving average price is $2.61 and its 200-day moving average price is $2.35.
Wall Street Analyst Weigh In
A number of analysts have issued reports on LAB shares. TD Cowen started coverage on Standard BioTools in a research report on Tuesday, April 16th. They issued a "buy" rating and a $3.50 target price on the stock. Jefferies Financial Group started coverage on Standard BioTools in a research report on Thursday, April 4th. They issued a "buy" rating and a $3.25 target price on the stock.
Check Out Our Latest Stock Report on LAB
Insiders Place Their Bets
In other Standard BioTools news, Director Casdin Partners Master Fund, L purchased 250,000 shares of the company's stock in a transaction on Monday, March 4th. The stock was acquired at an average price of $2.57 per share, for a total transaction of $642,500.00. Following the completion of the purchase, the director now directly owns 11,496,525 shares in the company, valued at approximately $29,546,069.25. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 53.10% of the company's stock.
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Recommended Stories
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
